Global Information
회사소개 | 문의 | 위시리스트

DNA 상해반응(DDR) 암 치료제 : 분석 툴

DNA Damage Response (DDR) Drugs in Oncology: Analytical Tool

리서치사 BioSeeker Group AB
발행일 2018년 12월 상품 코드 755823
페이지 정보 영문
가격
US $ 3,950 ₩ 4,656,000 Desktop App plus Online Access to Updates (One Year) - Single User
US $ 7,900 ₩ 9,312,000 Desktop App plus Online Access to Updates (One Year) - Site License
US $ 11,850 ₩ 13,968,000 Desktop App plus Online Access to Updates (One Year) - Global License


DNA 상해반응(DDR) 암 치료제 : 분석 툴 DNA Damage Response (DDR) Drugs in Oncology: Analytical Tool
발행일 : 2018년 12월 페이지 정보 : 영문

DNA 상해반응(DDR)은 세포의 게놈 무결성을 유지하는 데 필수적이며, 파괴는 암의 특징 중 하나입니다. 정상세포에 대한 영향을 최소화하면서 암세포를 우선적으로 사멸시키기 위한 DDR 상해에 대한 표적화는 암생존률을 향상시키기 위해서 보다 선택적이고 보다 인용성이 높은 치료법이 될 잠재력을 가지고 있습니다.

본 툴은 DNA 상해반응(DDR: DNA Damage Response,) 암 치료제 개발에 종사하는 399개사 이상의 기업과 파트너의 최신 동향을 집계한 것으로, 835종 치료제(그 중 412건이 226종 표적을 대상으로 한 암 치료제로서 적극적인 개발 단계)에 관한 각종 데이터를 온라인 액세스를 통해 제공하고 있습니다.

제공 내용

  • 분석 툴
    • 1년간 온라인 액세스
    • 내용 및 특집 격주 업데이트
    • 파이프라인 알림
    • 온라인 지원
    • 데이터 내용
      • 각종 계약과 협업
      • 신기술 및 약제
      • 기금, 보조금, 기업공개(IPO)
      • 신청 및 승인
      • 최신 임상시험 동향과 결과
      • 새로 시작된 임상시험
      • 주요 학회 정보
        • AACR
        • ASCO
        • ASGCT
        • ASH
        • CIMT
        • EHA
        • EORTC-NCI-AACR
        • ESMO
        • SITC
        • BIO(세계, 유럽, 아시아)
      • 바이오마커/동반진단약 개발
      • 병용요법 옵션
      • 적응증 선정 및 확대
      • 신약 재창출(Drug Repositioning) 기회 등
LSH 19.01.09

DNA Damage Response (DDR) is essential for maintaining the genomic integrity of the cell, and its disruption is one of the hallmarks of cancer. Targeting DDR deficiencies to preferentially kill cancer cells, while minimizing the impact on normal cells, has potential for more selective, better tolerated therapies to improve survival in multiple cancers.

DNA Damage Response (DDR) Drugs in Oncology: Analytical Tool is the must have handbook for any business developer, BI/CI operative or clinical developer who needs to be on top of this hot and fast moving area of oncology. This unique product is truly the only tool of its kind and is designed to give you a competitive edge in your DDR drug surveillance and intelligence, allowing you to power your decision making and advance your own interests.

Keeping you "In the know"

Simply put, our mission is to fuel your knowledge of oncology, to make you the first to know about very early technologies and startups, emerging clinical trial results, drug approvals and the ever-changing competitive landscape. DNA Damage Response (DDR) Drugs in Oncology: Analytical Tool achieves this by continuously scanning development in DDR and reporting:

  • Deals & Collaborations
  • New technologies/drugs (emerging from patents, grants, abstracts (see Conference Coverage) etc.)
  • Funding/Grants/IPOs
  • Filings & Approvals
  • Latest Clinical Trial Development & Results
  • Newly launched clinical trials
  • Conference Coverage of the world's twelve leading meetings in oncology*
  • Quarterly & Annual Reporting

This puts you in control of most, if not all, day-to-day developments in your field while also benefiting from one of the most comprehensive commercial pipeline review & competitive assessment tools available on the market today! Identify, prioritize, and lead scientific assessment of oncology opportunities and competition by multiple factors such as:

  • Emerging Technologies
  • Target Novelty
  • Recent Funding
  • Early & Late Stage Pipeline
  • Biomarker/Companion Diagnostic Development (featured below)
  • Entered Deals & Alliances
  • Conference surveillance of world leading cancer meetings (featured below)
  • Combination Therapy Choices (featured below)
  • Outcome of Clinical Trials
  • Indication Selection & Expansion Choices
  • Drug Repositioning Opportunities

For 20 years we have supported better decision making across the oncology drug development industry. Your DNA Damage Response (DDR) Drugs in Oncology: Analytical Tool is based on two decades of proven methodology and transforms your computer's desktop into a high capacity workbench within your area of choice. Even before launching this tool you have already eliminated the hundreds of hours of work needed to discover, process and piece together the thousands of sources that our team of oncology dedicated and highly experienced contents specialists have done on your behalf.

Your DNA Damage Response (DDR) Drugs in Oncology: Analytical Tool covers more than 399 companies plus partners who are today developing 835 DDR drugs where of 412 are in active development in cancer across 226 different targets. Any data and/or analysis from the Analytical Tool is yours to keep and data/graphs/tables can be easily exported into Excel/PDF and various graphic formats for mixing with your own proprietary information.

Let our expertise work for you

With a simple point and click interface you can navigate the environment of current development, drill down into specific areas such as ongoing combination trials, biomarker analysis, selected scientific abstracts etc. and generate drug profiles, drug target profiles and company profiles (including Business Development & Licensing contacts). Any analysis generated by you is packed with presentation-ready graphs and tables to use in your reports and presentations.

Your key to access development at the world-leading cancer meetings

The DNA Damage Response (DDR) Drugs in Oncology: Analytical Tool is continuously updated according to twelve of the world's most influential meetings in oncology (AACR, ASCO, ASGCT, ASH, CMIT, EHA, EORTC-NCI-AACR, ESMO, SITC and BIO (International, Europe and Asia). If you are not able to attend any of the conference(s) in person, this Analytical Tool ensures that you are not missing out on the important take home messages you need to know about.

Run combination therapy analysis like no other

The DNA Damage Response (DDR) Drugs in Oncology: Analytical Tool delivers comprehensive combination therapy analysis, allowing you to analyze combination therapies from multiple perspectives; from a single drug to virtually any cross section of oncology drugs of interest.

Unparalleled biomarker surveillance

We also provide an outstanding oncology clinical biomarker surveillance & analysis, highlighting clinical phenotyping and patient stratification in trials. This analysis is based on our monitoring of the presence and usage of more than 1,000 biomarkers across tens of thousands of cancer clinical trials.

Support and inspiration at your finger-tips

You also have access to a great selection of How-to Training Videos showing best practice approaches to aspects such as competitive pipeline analysis right through to many real world case examples put forward by other users of our Analytical Tools.

A tool to grow with and keep you informed

Unlike a static report which just represents a particular snapshot in time, all of the Analytical Tools come with one year of online access to twice-weekly updates in both contents and features, pipeline alerts and online support etc. You can choose to renew your access to these updates and support on a yearly basis or go over to our industry leading full service platform covering all oncology drug development, 1stOncology.

System Requirements

  • Browser Application (Supports: Internet Explorer, FireFox, Chrome and Safari))
  • Internet access
Back to Top
전화 문의
F A Q